Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus
B Raman, DA Bluemke, TF Lüscher… - European heart …, 2022 - academic.oup.com
Emerging as a new epidemic, long COVID or post-acute sequelae of coronavirus disease
2019 (COVID-19), a condition characterized by the persistence of COVID-19 symptoms …
2019 (COVID-19), a condition characterized by the persistence of COVID-19 symptoms …
A guide to immunotherapy for COVID-19
FL van de Veerdonk, E Giamarellos-Bourboulis… - Nature medicine, 2022 - nature.com
Immune dysregulation is an important component of the pathophysiology of COVID-19. A
large body of literature has reported the effect of immune-based therapies in patients with …
large body of literature has reported the effect of immune-based therapies in patients with …
Current and novel biomarkers of thrombotic risk in COVID-19: a consensus statement from the international COVID-19 thrombosis biomarkers colloquium
Abstract Coronavirus disease 2019 (COVID-19) predisposes patients to thrombotic and
thromboembolic events, owing to excessive inflammation, endothelial cell activation and …
thromboembolic events, owing to excessive inflammation, endothelial cell activation and …
Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with …
AC Spyropoulos, M Goldin, D Giannis… - JAMA internal …, 2021 - jamanetwork.com
Importance Hospitalized patients with COVID-19 are at risk for venous and arterial
thromboembolism and death. Optimal thromboprophylaxis dosing in high-risk patients is …
thromboembolism and death. Optimal thromboprophylaxis dosing in high-risk patients is …
Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid …
Objective To evaluate the effects of therapeutic heparin compared with prophylactic heparin
among moderately ill patients with covid-19 admitted to hospital wards. Design Randomised …
among moderately ill patients with covid-19 admitted to hospital wards. Design Randomised …
Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre …
E Ramacciotti, LB Agati, D Calderaro, VCR Aguiar… - The Lancet, 2022 - thelancet.com
Background Patients hospitalised with COVID-19 are at risk for thrombotic events after
discharge; the role of extended thromboprophylaxis in this population is unknown. Methods …
discharge; the role of extended thromboprophylaxis in this population is unknown. Methods …
2021 focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: executive summary
The consensus of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in
atrial fibrillation (AF) has been published in 2017 which provided useful clinical guidance for …
atrial fibrillation (AF) has been published in 2017 which provided useful clinical guidance for …
Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial
Importance Acutely ill inpatients with COVID-19 typically receive antithrombotic therapy,
although the risks and benefits of this intervention among outpatients with COVID-19 have …
although the risks and benefits of this intervention among outpatients with COVID-19 have …
COVID-19 therapeutics: Challenges and directions for the future
PC Robinson, DFL Liew, HL Tanner… - Proceedings of the …, 2022 - National Acad Sciences
The emergence of SARS-CoV-2 triggering the COVID-19 pandemic ranks as arguably the
greatest medical emergency of the last century. COVID-19 has highlighted health disparities …
greatest medical emergency of the last century. COVID-19 has highlighted health disparities …
[HTML][HTML] ISTH guidelines for antithrombotic treatment in COVID‐19
S Schulman, M Sholzberg, AC Spyropoulos… - Journal of Thrombosis …, 2022 - Elsevier
Antithrombotic agents reduce risk of thromboembolism in severely ill patients. Patients with
coronavirus disease 2019 (COVID‐19) may realize additional benefits from heparins …
coronavirus disease 2019 (COVID‐19) may realize additional benefits from heparins …